

Kidney Cancer GCOM 7 minutes

Kidney Cancer update – committee meeting 7 minutes

Date: 04/11/2024

Location: Virtual

Minutes: Final

Committee members present:		
Ana Semedo	Vice Chair	Present for items 1 – 9
Axel Bex	Urological Surgeon	Present for items 1, 8 & 9
Lisa Browning	Histopathologist	Present for items 1 – 9
Amarnath Challapalli	Clinical Oncologist (general)	Present for items 2 – 9
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1 – 7
John Connolly	Lay Member	Present for items 1 – 9
Geraldine Fox	Lay Member	Present for items 1 – 9
Fayiza Habeeb	Lead Nurse Practitioner	Present for items 1 – 9
David Mole	Nephrologist (co-opted member)	Present for items 1 – 9
Sandeep Singh Randhawa	General Practitioner	Present for items 1 – 9
Grant Stewart	Topic Adviser	Present for item 6
Rose Woodward	Lay Member	Present for items 1 – 9

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1 – 9
Fisayo Abba-Abba	Technical Analyst	Present for items 1 – 9
Sarah Boyce	Senior Technical Analyst	Present for items 1 – 9
Lindsay Claxton	Health Economic Adviser	Present for items 1 – 9
Olivia Crane	Senior Technical Analyst	Present for items 1 – 9
Gareth Haman	Senior Guidance Content Designer	Present for items 1 – 9
Jon Littler	Project Manager	Present for items 1 – 9
Agnesa Mehmeti	Technical Analyst	Present for items 1 – 9
Charlotte Rawstrone	Technical Analyst	Present for items 1 – 9
Hannah Tebbs	Senior Health Economist	Present for items 1 – 9
Fernando Zanghelini	Technical Analyst	Present for items 1 – 9
Yuan Yuan Zhang	Health Economist	Present for items 1 – 9

Apologies:	
Baljit Singh	Committee Chair
Janet Brown	Medical Oncologist, Committee Member
Stuart Evans	Oncology Pharmacist, Committee Member
Vishal Patil	Anaesthetist, Co-opted member
Ankit Rao	Medical Oncologist, Committee Member
Katherine Saxby	Medicines Adviser, Medicines Optimisation, NICE
Maxine Tran	Urological Surgeon, Committee Member
Tze Min Wah	Interventional Radiologist, Committee Member
Sam Withey	Diagnostic Radiologist, Committee Member
James Whitworth	Clinical Geneticist, Co-opted member

1. Welcome, Introductions and DOIs

The Vice Chair, Ana Semedo (AS) welcomed the committee members and NICE attendees to the 7th committee meeting for the NICE Kidney Cancer guideline. AS informed attendees that apologies had been received as noted above. AS asked all committee members to verbally declare any new interests, but there were no new interests to declare.

It was then noted by AS and Jon Littler (JL) the Project Manager that this meeting would likely be on-quorate, so it was agreed that any recommendations drafted at this meeting would require ratification at committee 8.

Finally, the minutes from committee 6 were checked and agreed to be an accurate record.

2. Review question 2c – Prognostic models for predicting survival or recurrence of non-metastatic breast cancer

The Chair introduced Agnesa Mehmeti (AM) Technical Analyst and Sarah Boyce (SB) Senior Technical Analyst to present the clinical evidence on clear cell and all types of renal cell carcinoma (RCC).

They took questions from the committee on the criteria used to select evidence and the quality of the evidence, before AS introduced Hannah Tebbs (HT) Senior Health Economist, to give a brief presentation on the health economic evidence.

AS also introduced Marie Harrisingh (MH) Topic Lead, to guide the committee on drafting recommendations for clear cell RCC.

3. Review question 2c (continued)

After a brief break, AM and SB returned to present the clinical evidence for papillary and chromophobe RCC before moving on to the drafting of recommendations with the support of the committee.

AS thanked the presenters and committee for their contributions that morning and moved on to the next item on the agenda.

4. Equality and health inequality considerations

SB remained as presenter and took the committee through the equalities issues identified by the scoping stage Equality and Health Inequalities Impact Assessment. They were asked if there were any additional issues they wanted to raise in light of the evidence presented so far in development.

After taking feedback from the committee, AS moved the conversation on to the next item on the agenda.

5. Revisiting draft recommendations for review 2c

For the final item of the morning, AS introduced MH to revisit the draft recommendations.

Firstly, MH asked the committee to revisit the recommendations made for review 2c to see if they were satisfied with the existing wording, whether they made sense together and if any additional recommendations needed to be made. Secondly, she led a discussion on the drafting of potential research recommendations relating to this topic.

The committee offered their feedback before AS thanked the team for the morning's presentations, and the committee for their feedback, and broke the meeting for lunch.

6. Review question 5b – Follow-up and monitoring for previously treated renal cell carcinoma

For the first item of the afternoon, AS introduced Yuanyuan Zhang (YS) Health Economist, who led a discussion on health economic modelling on risk-stratified follow up for review question 5b.

YZ took questions from the committee before AS moved the meeting on to the penultimate agenda item.

7. Review question 5a – Follow-up and monitoring of untreated renal masses using active surveillance

For the penultimate item, AS introduced Fisayo Abba-Abba (FA) Technical Analyst, Olivia Crane (OC) Senior Technical Analyst to lead a discussion on review question 5a.

FA and OC began the discussion with a presentation of the clinical evidence for this review question where, as with the morning session, they took questions from the committee on the criteria used to select evidence and the quality of the evidence.

HT discussed the health economic evidence with the committee.

8. Review question 5a – Drafting recommendations

The final item of the day was led by MH and was a discussion of potential recommendations that could be drawn out of the previous presentation of evidence on review question 5a, including possible research recommendations. The committee offered their input on priority recommendations and how they should be worded before AS moved on to the final item of the day.

9. Next steps and AOB

AS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AS brought the meeting to a close.

Date of next meeting: 12/12/2024

Location of next meeting: Virtual